The role of metallothionein in oncogenesis and cancer prognosis

Progress in Histochemistry and Cytochemistry

Volumn 44, Issue 1, 2009, Pages 29-64

  Pedersen, Mie Ø ^a   Larsen, Agnete ^b   Stoltenberg, Meredin ^b   Penkowa, Milena ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CATECHOLAMINE; CISPLATIN; CYTARABINE; CYTOKINE; FLUOROURACIL; GLUCOCORTICOID; MELPHALAN; MESSENGER RNA; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TUMOR MARKER; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; CYTOKINE PRODUCTION; DNA RESPONSIVE ELEMENT; DOWN REGULATION; ENZYME REGULATION; ESOPHAGUS CANCER; GENETIC TRANSCRIPTION; HEMATOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LARYNX CANCER; LIVER CANCER; LUNG CANCER; ONCOGENE; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PHARYNX CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; SKIN CANCER; STOMACH CANCER; THYROID CANCER; TUMOR CLASSIFICATION; TUMOR GROWTH;

HUMANS; METALLOTHIONEIN; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 63649149462     PISSN: 00796336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.proghi.2008.10.001     Document Type: Article

References (186)

1. Abdel-Latif MM, Kelleher D, Reynolds JV. Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J Surg Res 2008, 10 January [Epub ahead of print].
2. Abdel-Mageed A.B., and Agrawal K.C. Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. Cancer Res 58 (1998) 2335-2338
3. Arnott C.H., Scott K.A., Moore R.J., Robinson S.C., Thompson R.G., and Balkwill F.R. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23 (2004) 1902-1910
4. Arvanitis C., and Felsher D.W. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 16 (2006) 313-317
5. Athanassiadou P., Bantis A., Gonidi M., Athanassiades P., Agelonidou E., Grapsa D., et al. The expression of metallothioneins on imprint smears of prostate carcinoma: correlation with clinicopathologic parameters and tumor proliferative capacity. Tumori 93 (2007) 189-194
6. Bay B.H., Jin R., Huang J., and Tan P.H. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med (Maywood) 231 (2006) 1516-1521
7. Belpomme D., Irigaray P., Hardell L., Clapp R., Montagnier L., Epstein S., et al. The multitude and diversity of environmental carcinogens. Environ Res 105 (2007) 414-429
8. Bertin G., and Averbeck D. Cadmium: cellular effects, modifications of biomolecules, modulation of DNA repair and genotoxic consequences (a review). Biochimie 88 (2006) 1549-1559
9. Borges Júnior P.C., Ribeiro R.I., Cardoso S.V., Berbet A.L., Rocha A., Espindola F.S., et al. Metallothionein immunolocalization in actinic skin nonmelanoma carcinomas. Appl Immunohistochem Mol Morphol 15 (2007) 165-169
10. Bouzourene H., Chaubert P., Gebhard S., Bosman F.T., and Coucke P. Role of metallothioneins in irradiated human rectal carcinoma. Cancer 95 (2002) 1003-1008
11. Bradford T.J., Tomlins S.A., Wang X., and Chinnaiyan A.M. Molecular markers of prostate cancer. Urol Oncol 24 (2006) 538-551
12. Brahimi-Horn M.C., Chiche J., and Pouysségur J. Hypoxia and cancer. J Mol Med 85 (2007) 1301-1307
13. Brown J.J., Xu H., Nishitani J., Mohammed H., Osborne R., Teklehaimanot S., et al. Potential biomarkers for head and neck squamous cell carcinoma. Laryngoscope 113 (2003) 393-400
14. Butler J.S., and Loh S.N. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry 42 (2003) 2396-2403
15. Cai L., and Cherian M.G. Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium-metallothioneins. Toxicol Lett 136 (2003) 193-198
16. Cai L., Cherian M.G., Iskander S., Leblanc M., and Hammond R.R. Metallothionein induction in human CNS in vitro: neuroprotection from ionizing radiation. Int J Radiat Biol 76 (2000) 1009-1017
17. Cai L., Iskander S., Cherian M.G., and Hammond R.R. Zinc- or cadmium-pre-induced metallothionein protects human central nervous system cells and astrocytes from radiation-induced apoptosis. Toxicol Lett 146 (2004) 217-226
18. Cai L., Wang Y., Zhou G., Chen T., Song Y., Li X., et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 48 (2006) 1688-1697
19. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, et al. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 2008, June 25 [Epub ahead of print].
20. Cardoso S.V., Barbosa H.M., Candellori I.M., Loyola A.M., and Aguiar M.C. Prognostic impact of metallothionein on oral squamous cell carcinoma. Virchows Arch 441 (2002) 174-178
21. Carpenè E., Andreani G., and Isani G. Metallothionein functions and structural characteristics. J Trace Elem Med Biol 21 Suppl. 1 (2007) 35-39
22. Chan K.Y., Lai P.B., Squire J.A., Beheshti B., Wong N.L., Sy S.M., et al. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod Pathol 19 (2006) 1546-1554
23. Cherian M.G., and Kang Y.J. Metallothionein and liver cell regeneration. Exp Biol Med (Maywood) 231 (2006) 138-144
24. Cherian M.G., Jayasurya A., and Bay B.H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533 (2003) 201-209
25. Chimienti F., Seve M., Richard S., Mathieu J., and Favier A. Role of cellular zinc in programmed cell death: temporal relationship between zinc depletion, activation of caspases, and cleavage of Sp family transcription factors. Biochem Pharmacol 62 (2001) 51-62
26. Coyle P., Philcox J.C., Carey L.C., and Rofe A.M. Metallothionein: the multipurpose protein. Cell Mol Life Sci 59 (2002) 627-647
27. Dalgin G.S., Drever M., Williams T., King T., DeLisi C., and Liou L.S. Identification of novel epigenetic markers for clear cell renal cell carcinoma. J Urol 180 (2008) 1126-1130
28. Datta J., Majumder S., Kutay H., Motiwala T., Frankel W., Costa R., et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 67 (2007) 2736-2746
29. De Bont R., and van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 19 (2004) 169-185
30. Duncan E.L., and Reddel R.R. Downregulation of metallothionein-IIA expression occurs at immortalization. Oncogene 18 (1999) 897-903
31. Dutsch-Wicherek M., Popiela T.J., Klimek M., Rudnicka-Sosin L., Wicherek L., Oudinet J.P., et al. Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuro Endocrinol Lett 26 (2005) 567-574
32. Dutsch-Wicherek M., Sikora J., and Tomaszewska R. The possible biological role of metallothionein in apoptosis. Front Biosci 13 (2008) 4029-4038
33. Dziegiel P. Expression of metallothioneins in tumor cells. Pol J Pathol 55 (2004) 3-12
34. Ebadi M., Brown-Borg H., El Refaey H., Singh B.B., Garrett S., Shavali S., et al. Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease. Brain Res Mol Brain Res 134 (2005) 67-75
35. Ebert M.P., Günther T., Hoffmann J., Yu J., Miehlke S., Schulz H.U., et al. Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Res 60 (2000) 1995-2001
36. Eid H., Géczi L., Bodrogi I., Institoris E., and Bak M. Do metallothioneins affect the response to treatment in testis cancers?. J Cancer Res Clin Oncol 124 (1998) 31-36
37. El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Young H.A., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000) 398-402
38. El Sharkawy S.L., and Farrag A.R. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status. Appl Immunohistochem Mol Morphol 16 (2008) 108-112
39. Endo T., Yoshikawa M., Ebara M., Kato K., Sunaga M., Fukuda H., et al. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol 39 (2004) 1196-1201
40. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 45 (2005) 629-656
41. Fan L.Z., and Cherian M.G. Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer 87 (2002) 1019-1026
42. Fang J., Nakamura H., and Iyer A.K. Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 15 (2007) 475-486
43. Feng W., Cai J., Pierce W.M., Franklin R.B., Maret W., Benz F.W., et al. Metallothionein transfers zinc to mitochondrial aconitase through a direct interaction in mouse hearts. Biochem Biophys Res Commun 332 (2005) 853-858
44. Ferrario C., Lavagni P., Gariboldi M., Miranda C., Losa M., Cleris L., et al. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 88 (2008) 474-481
45. Formigari A., Irato P., and Santon A. Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: biochemical and cytochemical aspects. Comp Biochem Physiol C Toxicol Pharmacol 146 (2007) 443-459
46. Gallicchio L.M., Flaws J.A., Fowler B.A., and Ioffe O.B. Metallothionein expression in invasive and in situ breast carcinomas. Cancer Detect Prev 29 (2005) 332-337
47. Garrett S.H., Sens M.A., Shukla D., Flores L., Somji S., Todd J.H., et al. Metallothionein isoform 1 and 2 gene expression in the human prostate: downregulation of MT-1X in advanced prostate cancer. Prostate 43 (2000) 125-135
48. Garza-González E., Bosques-Padilla F.J., El-Omar E., Hold G., Tijerina-Menchaca R., Maldonado-Garza H.J., et al. Role of the polymorphic IL-1B, IL-1RN and TNF-A genes in distal gastric cancer in Mexico. Int J Cancer 114 (2005) 237-241
49. Goncharova E.I., and Rossman T.G. A role for metallothionein and zinc in spontaneous mutagenesis. Cancer Res 54 (1994) 5318-5323
50. Groenbaek K., Hother C., and Jones P.A. Epigenetic changes in cancer. APMIS 115 (2007) 1039-1059
51. Habeebu S.S., Liu J., Liu Y., and Klaassen C.D. Metallothionein-null mice are more sensitive than wild-type mice to liver injury induced by repeated exposure to cadmium. Toxicol Sci 55 (2000) 223-232
52. Hagrman D., Goodisman J., Dabrowiak J.C., and Souid A.K. Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab Dispos 31 (2003) 916-923
53. Hainaut P., and Mann K. Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal 3 (2001) 611-623
54. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
55. Haq F., Mahoney M., and Koropatnick J. Signaling events for metallothionein induction. Mutat Res 533 (2003) 211-226
56. Hengstler J.G., Pilch H., Schmidt M., Dahlenburg H., Sagemüller J., Schiffer I., et al. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer 95 (2001) 121-127
57. Henrique R., Jerónimo C., Hoque M.O., Nomoto S., Carvalho A.L., Costa V.L., et al. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1274-1278
58. Hinkel A., Schmidtchen S., Palisaar R.J., Noldus J., and Pannek J. Identification of bladder cancer patients at risk for recurrence or progression: an immunohistochemical study based on the expression of metallothionein. J Toxicol Environ Health A 71 (2008) 954-959
59. Hishikawa Y., Koji T., Dhar D.K., Kinugasa S., Yamaguchi M., and Nagasue N. Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer 81 (1999) 712-720
60. Hofseth L.J. Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. Cancer Lett 268 (2008) 10-30
61. Hold G.L., and El-Omar M.E. Genetic aspects of inflammation and cancer. Biochem J 410 (2008) 225-235
62. Huang M., Shaw III C.F., and Petering D.H. Interprotein metal exchange between transcription factor IIIA and metallothionein. J Inorg Biochem 98 (2004) 639-648
63. Huang Y., de la Chapelle A., and Pellegata N.S. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 104 (2003) 735-744
64. Iizuka N., Oka M., Yamada-Okabe H., Mori N., Tamesa T., Okada T., et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62 (2002) 3939-3944
65. Iizuka N., Oka M., Yamada-Okabe H., Mori N., Tamesa T., Okada T., et al. Self-organizing-map-based molecular signature representing the development of hepatocellular carcinoma. FEBS Lett 579 (2005) 1089-1100
66. Ioachim E., Assimakopoulos D., Peschos D., Zissi A., Skevas A., and Agnantis N.J. Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract 195 (1999) 809-814
67. Ioachim E.E., Charchanti A.V., Stavropoulos N.E., Athanassiou E.D., Michael M.C., and Agnantis N.J. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices. Anticancer Res 21 (2001) 1757-1761
68. Irigaray P., Newby J.A., Clapp R., Hardell L., Howard V., Montagnier L., et al. Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed Pharmacother 61 (2007) 640-658
69. Ishii K., Usui S., Yamamoto H., Sugimura Y., Tatematsu M., and Hirano K. Decreases of metallothionein and aminopeptidase N in renal cancer tissues. J Biochem 129 (2001) 253-258
70. Ito H., Kaneko K., Makino R., Konishi K., Kurahashi T., Yamamoto T., et al. Interleukin-1beta gene in esophageal, gastric and colorectal carcinomas. Oncol Rep 18 (2007) 473-481
71. Izzo J.G., Malhotra U., Wu T.T., Ensor J., Luthra R., Lee J.H., et al. Association of activated transcription factor nuclear factor kappaB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24 (2006) 748-754
72. Jacob S.T., Majumder S., and Ghoshal K. Suppression of metallothionein-I/II expression and its probable molecular mechanisms. Environ Health Perspect 110 (2002) 827-830
73. Janssen A.M., van Duijn W., Oostendorp-Van De Ruit M.M., Kruidenier L., Bosman C.B., Griffioen G., et al. Metallothionein in human gastrointestinal cancer. J Pathol 192 (2000) 293-300
74. Janssen A.M., van Duijn W., Kubben F.J., Griffioen G., Lamers C.B., van Krieken J.H., et al. Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Cancer Res 8 (2002) 1889-1896
75. Jia G., Sone H., Nishimura N., Satoh M., and Tohyama C. Metallothionein (I/II) suppresses genotoxicity caused by dimethylarsinic acid. Int J Oncol 25 (2004) 325-333
76. Jiang L.J., Maret W., and Vallee B.L. The glutathione redox couple modulates zinc transfer from metallothionein to zinc depleted sorbitol dehydrogenase. Proc Natl Acad Sci USA 95 (1998) 3483-3488
77. Jin R., Bay B.H., Chow V.T., Tan P.H., and Lin V.C. Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. Br J Cancer 83 (2000) 319-323
78. Jin R., Bay B.H., Chow V.T., and Tan P.H. Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat 66 (2001) 265-272
79. Jin R., Chow V.T., Tan P.H., Dheen S.T., Duan W., and Bay B.H. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 23 (2002) 81-86
80. Joseph M.G., Banerjee D., Kocha W., Feld R., Stitt L.W., and Cherian M.G. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 92 (2001) 836-842
81. Kelly E.J., and Palmiter R.D. A murine model of Menkes disease reveals a physiological function of metallothionein. Nat Genet 13 (1996) 219-222
82. Kennette W., Collins O.M., Zalups R.K., and Koropatnick J. Basal and zinc-induced metallothionein in resistance to cadmium, cisplatin, zinc, and tert-butyl hydroperoxide: studies using MT knockout and antisense-downregulated MT in mammalian cells. Toxicol Sci 88 (2005) 602-613
83. Klaassen C.D., Choudhuri S., McKim Jr. J.M., Lehman-McKeeman L.D., and Kershaw W.C. In vitro and in vivo studies on the degradation of metallothionein. Environ Health Perspect 102 (1994) 141-146
84. Klaassen C.D., Liu J., and Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol 39 (1999) 267-294
85. Kondo Y., Woo E.S., Michalska A.E., Choo K.H.A., and Lazo J.S. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res 55 (1995) 2021-2023
86. Kondo Y., Rusnak J.M., Hoyt D.G., Settineri C.E., Pitt B.R., and Lazo J.S. Enhanced apoptosis in metallothionein null cells. Mol Pharmacol 52 (1997) 195-201
87. Korshunov A., Sycheva R., Timirgaz V., and Golanov A. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol 45 (1999) 219-227
88. Kraker A., Schmidt J., Krezoski S., and Petering D.H. Binding of cisdichlorodiammine platinum(II) to metallothionein in Ehrlich cells. Biochem Biophys Res Commun 130 (1985) 786-792
89. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008, March 16.
90. Laird P.W. Cancer epigenetics. Hum Mol Genet 14 (2005) R65-R76
91. Lu D.D., Chen Y.C., Zhang X.R., Cao X.R., Jiang H.Y., and Yao L. The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma. Yale J Biol Med 76 (2003) 55-62
92. Maret W., Larsen K.S., and Vallee B.L. Co-ordination dynamics of biological zinc ''clusters'' in metallothioneins and in the DNA binding domain of the transcription factor Gal4. Proc Natl Acad Sci USA 94 (1997) 2233-2237
93. Maret W., Jacob C., Vallee B.L., and Fischer E.H. Inhibitory sites in enzymes: zinc removal and reactivation by thionein. Proc Natl Acad Sci USA 96 (1999) 1936-1940
94. Matés J.M., Segura J.A., Alonso F.J., and Márquez J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 82 (2008) 273-299
95. McCluggage W.G., Maxwell P., and Bharucha H. Immunohistochemical detection of metallothionein and MIB1 in uterine cervical squamous lesions. Int J Gynecol Pathol 17 (1998) 29-35
96. Meffert M.K., and Baltimore D. Physiological functions for brain NF-kappaB. Trends Neurosci 28 (2005) 37-43
97. Meijer C., Timmer A., De Vries E.G., Groten J.P., Knol A., Zwart N., et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85 (2000) 777-781
98. Meplan C., Richard M.J., and Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 19 (2000) 5227-5236
99. Miles A.T., Hawksworth G.M., Beattie J.H., and Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol 35 (2000) 35-70
100. Mita M., Satoh M., Shimada A., Okajima M., Azuma S., Suzuki J.S., et al. Metallothionein is a crucial protective factor against Helicobacter pylori-induced gastric erosive lesions in a mouse model. Am J Physiol Gastrointest Liver Physiol 294 (2008) G877-G884
101. Mitani T., Shirasaka D., Aoyama N., Miki I., Morita Y., Ikehara N., et al. Role of metallothionein in Helicobacter pylori-positive gastric mucosa with or without early gastric cancer and the effect on its expression after eradication therapy. J Gastroenterol Hepatol (2007) [Epub ahead of print]
102. Mitropoulos D., Kyroudi-Voulgari A., Theocharis S., Serafetinides E., Moraitis E., Zervas A., et al. Prognostic significance of metallothionein expression in renal cell carcinoma. World J Surg Oncol 3 1 (2005) 5 June 17
103. Miyashita H., and Sato Y. Metallothionein 1 is a downstream target of vascular endothelial zinc finger 1 (VEZF1) in endothelial cells and participates in the regulation of angiogenesis. Endothelium 12 (2005) 163-170
104. Monden N., Abe S., Sutoh I., Hishikawa Y., Kinugasa S., and Nagasue N. Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Oncology 54 (1997) 391-399
105. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5 (1999) 828-831
106. Muramatsu Y., Hasegawa Y., Fukano H., Ogawa T., Namuba M., Mouri K., et al. Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses. Anticancer Res 20 (2000) 257-264
107. Naito S., Koga H., Yokomizo A., Sakamoto N., Kotoh S., Nakashima M., et al. Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J Surg 24 (2000) 1183-1186
108. Naugler W.E., and Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18 (2008) 19-26
109. Nguyen A., Jing Z., Mahoney P.S., Davis R., Sikka S.C., Agrawal K.C., et al. In vivo gene expression profile analysis of metallothionein in renal cell carcinoma. Cancer Lett 160 (2000) 133-140
110. Nielsen A.E., Bohr A., and Penkowa M. The balance between life and death of cells: roles of metallothioneins. Biomarker Insights 2 (2007) 99-111
111. Oh B.R., Sasaki M., Perinchery G., Ryu S.B., Park Y.I., Carroll P., et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 163 (2000) 1584-1587
112. Ohshima H., Tatemichi M., and Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417 (2003) 3-11
113. Ohshima H., Tazawa H., Sylla B.S., and Sawa T. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res 591 (2005) 110-122
114. Ohshio G., Imamura T., Okada N., Wang Z.H., Yamaki K., Kyogoku T., et al. Immunohistochemical study of metallothionein in pancreatic carcinomas. J Cancer Res Clin Oncol 122 (1996) 351-355
115. Ostrakhovitch E.A., Olsson P.E., Jiang S., and Cherian M.G. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett 580 (2006) 1235-1238
116. Ostrakhovitch E.A., Olsson P.E., von Hofsten J., and Cherian M.G. p53 mediated regulation of metallothionein transcription in breast cancer cells. J Cell Biochem 102 (2007) 1571-1583
117. Pastuszewski W., Dziegiel P., Krecicki T., Podhorska-Okolow M., Ciesielska U., Gorzynska E., et al. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res 27 (2007) 335-342
118. Patel D.A., Presti Jr. J.C., McNeal J.E., Gill H., Brooks J.D., and King C.R. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23 (2005) 6157-6162
119. Penkowa M. Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J 273 (2006) 1857-1870
120. Penkowa M. Metallothionein I+II expression and roles during neuropathology in the CNS. Dan Med Bull 53 (2006) 105-121
121. Penkowa M., Carrasco J., Giralt M., Molinero A., Hernández J., Campbell I.L., et al. Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. J Cereb Blood Flow Metab 20 (2000) 1174-1189
122. Penkowa M., Espejo C., Martínez-Cáceres E.M., Poulsen C.B., Montalban X., and Hidalgo J. Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. J Neuroimmunol 119 (2001) 248-260
123. Penkowa M., and Hidalgo J. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J Neurosci Res 72 (2003) 574-586
124. Penkowa M., Espejo C., Martínez-Cáceres E.M., Montalban X., and Hidalgo J. Increased demyelination and axonal damage in metallothionein I+II-deficient mice during experimental autoimmune encephalomyelitis. Cell Mol Life Sci 60 (2003) 185-197
125. Penkowa M., Quintana A., Carrasco J., Giralt M., Molinero A., and Hidalgo J. Metallothionein prevents neurodegeneration and central nervous system cell death after treatment with gliotoxin 6-aminonicotinamide. J Neurosci Res 77 (2004) 35-53
126. Penkowa M., Florit S., Giralt M., Quintana A., Molinero A., Carrasco J., et al. Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res 79 (2005) 522-534
127. Penkowa M., Caceres M., Borup R., Nielsen F.C., Poulsen C.B., Quintana A., et al. Novel roles for metallothionein-I+II (MT-I+II) in defense responses, neurogenesis, and tissue restoration after traumatic brain injury: insights from global gene expression profiling in wild-type and MT-I+II knockout mice. J Neurosci Res 84 (2006) 1452-1474
128. Penkowa M., Tio L., Giralt M., Quintana A., Molinero A., Atrian S., et al. Specificity and divergence in the neurobiologic effects of different metallothioneins after brain injury. J Neurosci Res 83 (2006) 974-984
129. Perkins N.D. NF-kappaB: tumor promoter or suppressor?. Trends Cell Biol 14 (2004) 64-69
130. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8 (2007) 49-62
131. Perry D.K., Smyth M.J., Stennicke H.R., Salvesen G.S., Duriez P., Poirier G.G., et al. Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem 272 (1997) 18530-18533
132. Piotrowski A., Benetkiewicz M., Menzel U., de Ståhl T.D., Mantripragada K., Grigelionis G., et al. Microarray-based survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer. Genes Chromosomes Cancer 45 (2006) 656-667
133. Posewitz M.C., and Wilcox D.E. Properties of the Sp1 zinc finger 3 peptide: coordination chemistry, redox reactions and metal binding competition with metallothionein. Chem Res Toxicol 8 (1995) 1020-1028
134. Poulsen C.B., Borup R., Borregaard N., Nielsen F.C., Møller M.B., and Ralfkiaer E. Prognostic significance of metallothionein in B-cell lymphomas. Blood 108 (2006) 3514-3519
135. Quaife C.J., Cherne R.L., Newcomb T.G., Kapur R.P., and Palmiter R.D. Metallothionein overexpression suppresses hepatic hyperplasia induced by hepatitis B surface antigen. Toxicol Appl Pharmacol 155 (1999) 107-116
136. Reed J.C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111 (2008) 3322-3330
137. Ren J., Privratsky J.R., Yang X., Dong F., and Carlson E.C. Metallothionein alleviates glutathione depletion-induced oxidative cardiomyopathy in murine hearts. Crit Care Med 36 (2008) 2106-2116
138. Robertson F.M., Ross M.S., Tober K.L., Long B.W., and Oberyszyn T.M. Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifyline. Carcinogenesis 17 (1996) 1719-1728
139. Rossman T.G., and Goncharova E.I. Spontaneous mutagenesis in mammalian cells is caused mainly by oxidative events and can be blocked by antioxidants and metallothionein. Mutat Res 402 (1998) 103-110
140. Rossman T.G., Goncharova E.I., Nádas A., and Dolzhanskaya N. Chinese hamster cells expressing antisense to metallothionein become spontaneous mutators. Mutat Res 373 (1997) 75-85
141. Saga Y., Hashimoto H., Yachiku S., Tokumitsu M., and Kaneko S. Immunohistochemical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patient survival. J Urol 168 (2002) 2227-2231
142. Sakurai A., Hara S., Okano N., Kondo Y., Inoue J., and Imura N. Regulatory role of metallothionein in NF-kappaB activation. FEBS Lett 455 (1999) 55-58
143. Sato M., and Kondoh M. Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. Tohoku J Exp Med 196 (2002) 9-22
144. Sauerbrey A., Zintl F., and Volm M. Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia. Ann Hematol 69 (1994) 111-115
145. Sauerbrey A., Zintl F., Hermann J., and Volm M. Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL). Anticancer Res 18 (1998) 1231-1236
146. Sengupta S., Myers R.P., Slezak J.M., Bergstralh E.J., Zincke H., and Blute M.L. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
147. Shi H., Hudson L.G., and Liu K.J. Oxidative stress and apoptosis in metal ion-induced carcinogenesis. Free Radic Biol Med 37 (2004) 582-593
148. Shimoda R., Achanzar W.E., Qu W., Nagamine T., Takagi H., Mori M., et al. Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 73 (2003) 294-300
149. Siu L.L., Banerjee D., Khurana R.J., Pan X., Pflueger R., Tannock I.F., et al. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4 (1998) 559-565
150. Somji S., Sens M.A., Lamm D.L., Garrett S.H., and Sens D.A. Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev 25 (2001) 62-75
151. Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., and Fujiki H. Essential role of tumor necrosis factor-alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59 (1999) 4516-4518
152. Surowiak P., Materna V., Kaplenko I., Spaczyński M., Dietel M., Lage H., et al. Augmented expression of metallothionein and glutathione-S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 447 (2005) 626-633
153. Surowiak P., Materna V., Györffy B., Matkowski R., Wojnar A., Maciejczyk A., et al. Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer 95 (2006) 339-346
154. Surowiak P., Materna V., Maciejczyk A., Pudełko M., Markwitz E., Spaczyński M., et al. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450 (2007) 279-285
155. Suzuki J.S., Nishimura N., Zhang B., Nakatsuru Y., Kobayashi S., Satoh M., et al. Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null mice. Carcinogenesis 24 (2003) 1123-1132
156. Tai S.K., Tan O.J., Chow V.T., Jin R., Jones J.L., Tan P.H., et al. Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 163 (2003) 2009-2019
157. Tan O.J., Bay B.H., and Chow V.T. Differential expression of metallothionein isoforms in nasopharyngeal cancer and inhibition of cell growth by antisense down-regulation of metallothionein-2A. Oncol Rep 13 (2005) 127-131
158. Tao X., Zheng J.M., Xu A.M., Chen X.F., and Zhang S.H. Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res 37 (2007) 820-827
159. Tekur S., and Ho S.M. Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines. Mol Carcinog 33 (2002) 44-55
160. Tews D.S., Nissen A., Külgen C., and Gaumann A.K. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 50 (2000) 227-237
161. Theocharis S., Karkantaris C., Philipides T., Agapitos E., Gika A., Margeli A., et al. Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology 40 (2002) 143-151
162. Theocharis S.E., Margeli A.P., and Koutselinis A. Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 18 (2003) 162-169
163. Theocharis S.E., Margeli A.P., Klijanienko J.T., and Kouraklis G.P. Metallothionein expression in human neoplasia. Histopathology 45 (2004) 103-118
164. Thirumoorthy N., Manisenthil Kumar K.T., Shyam Sundar A., Panayappan L., and Chatterjee M. Metallothionein: an overview. World J Gastroenterol 13 (2007) 993-996
165. Tuccari G., Giuffre G., Arena F., and Barresi G. Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa. Histol Histopathol 15 (2000) 1035-1041
166. Tüzel E., Kirkali Z., Yörükoglu K., Mungan M.U., and Sade M. Metallothionein expression in renal cell carcinoma: subcellular localization and prognostic significance. J Urol 165 (2001) 1710-1713
167. Upadhyay R., Jain M., Kumar S., Ghoshal U.C., and Mittal B. Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol 128 (2008) 199-204
168. Valko M., Rhodes C.J., Moncol J., Izakovic M., and Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160 (2006) 1-40
169. van der Woude C.J., Kleibeuker J.H., Jansen P.L., and Moshage H. Chronic inflammation, apoptosis and (pre-) malignant lesions in the gastro-intestinal tract. Apoptosis 9 (2004) 123-130
170. Vita M., and Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16 (2006) 318-330
171. Volm M., Zintl F., Edler L., and Sauerbrey A. Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia. Med Pediatr Oncol 28 (1997) 117-126
172. Waalkes M.P., Liu J., Kasprzak K.S., and Diwan B.A. Hypersusceptibility to cisplatin carcinogenicity in metallothionein-I/II double knockout mice: production of hepatocellular carcinoma at clinically relevant doses. Int J Cancer 119 (2006) 28-32
173. Warzocha K., Ribeiro P., Bienvenu J., Roy P., Charlot C., Rigal D., et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91 (1998) 3574-3581
174. Wei H., Desouki M.M., Lin S., Xiao D., Franklin R.B., and Feng P. Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 7 (2008) 7
175. Weinlich G., Topar G., Eisendle K., Fritsch P.O., and Zelger B. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma. J Eur Acad Dermatol Venereol 21 (2007) 669-677
176. Wülfing C., van Ahlen H., Eltze E., Piechota H., Hertle L., and Schmid K.W. Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapy. World J Urol 25 (2007) 199-205
177. Yamasaki Y., Smith C., Weisz D., van Huizen I., Xuan J., Moussa M., et al. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder. Urology 67 (2006) 530-535
178. Yamasaki M., Nomura T., Sato F., and Mimata H. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep 18 (2007) 1145-1153
179. Yang M, Chitambar CR. Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med 2008, June 14 [Epub ahead of print].
180. Yang M., Kroft S.H., and Chitambar C.R. Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther 6 (2007) 633-643
181. Yang X., Doser T.A., Fang C.X., Nunn J.M., Janardhanan R., Zhu M., et al. Metallothionein prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: role of oxidative stress. FASEB J 20 (2006) 1024-1026
182. Youn J., Hwang S.H., Ryoo Z.Y., Lynes M.A., Paik D.J., Chung H.S., et al. Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta and down-regulation of proinflammatory mediators. Clin Exp Immunol 129 (2002) 232-239
183. Zelazowski A.J., Garvey J.S., and Hoeschele J.D. In vivo and in vitro binding of platinum to metallothionein. Arch Biochem Biophys 229 (1984) 246-252
184. Zeng J., Heuchel R., Schaffner W., and Kagi J.H. Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Sp1. FEBS Lett 279 (1991) 310-312
185. Zhou X.D., Sens D.A., Sens M.A., Namburi V.B., Singh R.K., Garrett S.H., et al. Metallothionein-1 and -2 expression in cadmium- or arsenic-derived human malignant urothelial cells and tumor heterotransplants and as a prognostic indicator in human bladder cancer. Toxicol Sci 91 (2006) 467-475
186. Zienolddiny S., Ryberg D., Maggini V., Skaug V., Canzian F., and Haugen A. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer 109 (2004) 353-356